Trial Profile
Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 15 Nov 2021 Status changed from recruiting to active, no longer recruiting.